Compare AbbVie Inc (ABBV) vs Fabrinet (FN) Price & Performance

AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).

Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.

FN trades at $500.75, up 0.23% with a bearish technical signal despite strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters with Q1 2026 EPS of $3.72 exceeding expectations. Analyst consensus remains strongly bullish with 75% buy ratings and a $733 price target, representing 46% upside potential from current levels. Recent news highlights FN's strategic position in AI optical supply chain with capacity expansion supporting multi-year growth visibility.

The outlook remains positive driven by AI infrastructure demand and strong execution, though premium valuation metrics (P/E 43.02) and technical bearish signals warrant caution. Key risks include datacom supply constraints and FX volatility, but robust revenue growth projections ($4.2B for 2026) and expanding margins support the bullish analyst stance.